"Cellipont is committed to enabling the next generation of cell therapies," said Darren Head, CEO of Cellipont Bioservices. "Integrating Ronawk's Bio-OS™ platform into our manufacturing capabilities ...

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/241216_stem-cell-lab.jpg Following exhaustive research, Adia ...

The study introduces a novel "multi-route" administration protocol for Wharton’s Jelly-derived Mesenchymal Stem Cells (WJ-MSCs). Unlike previous trials that relied on a single delivery method, this ...

A new study revealed that cellular kinetics, observable over a period of time rather than in a single snapshot, holds important information about long-term cellular quality and stemness. The proposed ...

CLD-101, a stem cell-based platform, delivers oncolytic viruses to tumors, targeting high-grade glioma in a phase 1b/2 trial. Previous trials demonstrated CLD-101's safety and potential efficacy, with ...

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, " Stem Cell Therapy ...

The chemical composition of cryogenically frozen materials that have remained hydrated is technically challenging to investigate due to the limited radiation resistance of hydrated living cells. This ...